Provided is a diagnostic method in which small-sized cfDNA is concentrated and isolated from a liquid sample such as urine, cerebrospinal fluid, plasma, blood, pleural fluid, or body fluid, and then a biomarker overexpressed in a specific cancer is detected with ultra-high sensitivity without PCR, and the method does not require a PCR amplification reaction and thus can greatly reduce time taken to diagnose cancer, and since it can be directly analyzed in the field, it can be used as a point-of-care testing (POCT) that can simultaneously search a large number of genes within a short time.

A sequencing system includes an automated sequencing instrument adapted to determine variant calls for one or more extracted polynucleotide samples with a performance of at least 98.5% raw read accuracy and a total instrument run time in a range of 16 hours to 22 hours to determine variant calls when sequencing 6 cfTNA extracted polynucleotide samples using a targeted assay with one nucleic acid pool per sample.

A sequencing system includes an automated sequencing instrument adapted to determine variant calls for one or more extracted polynucleotide samples with a performance of at least 98.5% raw read accuracy and a total instrument run time in a range of 16 hours to 22 hours to determine variant calls when sequencing 6 cfTNA extracted polynucleotide samples using a targeted assay with one nucleic acid pool per sample.

Provided are a kit for detecting Coronavirus using magnetic nanoparticles and a method detecting Coronavirus using the same. The kit for detecting Coronavirus includes a reactor having an opening on one side and provided with a sample containing Coronavirus, at least one magnetic nanoparticle part provided in the reactor, a conductive substrate provided to cover the opening of the reactor, and a magnetic field applying part for applying a magnetic field to the reactor, in which the magnetic nanoparticle part includes a magnetic nanoparticle including a core portion made of iron oxide and a shell portion made of gold and provided to surround the core portion, and a primer attached to the shell portion of the magnetic nanoparticle.

Provided are a kit for detecting Coronavirus using magnetic nanoparticles and a method detecting Coronavirus using the same. The kit for detecting Coronavirus includes a reactor having an opening on one side and provided with a sample containing Coronavirus, at least one magnetic nanoparticle part provided in the reactor, a conductive substrate provided to cover the opening of the reactor, and a magnetic field applying part for applying a magnetic field to the reactor, in which the magnetic nanoparticle part includes a magnetic nanoparticle including a core portion made of iron oxide and a shell portion made of gold and provided to surround the core portion, and a primer attached to the shell portion of the magnetic nanoparticle.

The invention provides a method of detecting a target polynucleotide in a sample comprising: (a) contacting the sample with a guide polynucleotide that binds to a sequence in the target polynucleotide and a polynucleotide-guided effector protein, wherein the guide polynucleotide and polynucleotide-guided effector protein form a complex with any target polynucleotide present in the sample; (b) contacting the sample with a membrane comprising a transmembrane pore; (c) applying a potential to the membrane; and (d) monitoring for the presence or absence of an effect resulting from the interaction of the complex with the transmembrane pore to determine the presence or absence of the complex, thereby detecting the target polynucleotide in the sample.

The invention provides a method of detecting a target polynucleotide in a sample comprising: (a) contacting the sample with a guide polynucleotide that binds to a sequence in the target polynucleotide and a polynucleotide-guided effector protein, wherein the guide polynucleotide and polynucleotide-guided effector protein form a complex with any target polynucleotide present in the sample; (b) contacting the sample with a membrane comprising a transmembrane pore; (c) applying a potential to the membrane; and (d) monitoring for the presence or absence of an effect resulting from the interaction of the complex with the transmembrane pore to determine the presence or absence of the complex, thereby detecting the target polynucleotide in the sample.

Disclosed herein is a detection device comprising sensors with spin torque oscillators (STOs), at least one fluidic channel configured to receive molecules to be detected, and detection circuitry coupled to the sensors. At least some of the molecules to be detected are labeled by magnetic nanoparticles (MNPs). The presence of one or more MNPs in the vicinity of a STO subjected to a bias current changes the oscillation frequency of the STO. The sensors are encapsulated by a material, such as an insulator, separating the sensors from the at least one fluidic channel. A surface of the material provides binding sites for the molecules to be detected. The detection circuitry is configured to detect changes in the oscillation frequencies of the sensors in response to presence or absence of one or more MNPs coupled to one or more binding sites associated with the sensors.

Disclosed herein is a detection device comprising sensors with spin torque oscillators (STOs), at least one fluidic channel configured to receive molecules to be detected, and detection circuitry coupled to the sensors. At least some of the molecules to be detected are labeled by magnetic nanoparticles (MNPs). The presence of one or more MNPs in the vicinity of a STO subjected to a bias current changes the oscillation frequency of the STO. The sensors are encapsulated by a material, such as an insulator, separating the sensors from the at least one fluidic channel. A surface of the material provides binding sites for the molecules to be detected. The detection circuitry is configured to detect changes in the oscillation frequencies of the sensors in response to presence or absence of one or more MNPs coupled to one or more binding sites associated with the sensors.

This disclosure relates to methods for spatial profiling of analytes present in a biological sample. Also provided are methods for using spatially barcoded arrays to detect a biological analyte in a cell comprising a small molecule.